CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma

The incidence of Hodgkin's lymphoma (HL) in Chinese children and adolescents is only 1 / 10 of that in Europe and the United States, which is a "rare" childhood tumor. Due to the "drug shortage" and extremely low incidence, it has brought great difficulties to the domestic clinical research and failed to achieve the desired effect. In this study, we apply a well-documented effective protocol on newly diagnosed children and adolescents with HL to understand whether the same treatment regimens can obtain similar event free survival rates and overall survival rates and then find out the problems existing in the current clinical care of HL in China, so as to make continuous improvement in the future and prepare for innovative clinical research.

NCT Number	NCT04726501
Lead Sponsor	Children's Cancer Group, China Collaborators: Shanghai Children's Medical Center
Conditions	Hodgkin Lymphoma
Enrollment	200 participants
Start Date	2018-04-01
Primary Completion	2025-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-19